T1	Participants 28 105	determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib
T2	Participants 119 247	Residual cardiovascular (CV) risk often remains high despite statin therapy to lower low-density lipoprotein cholesterol (LDL-C)
T3	Participants 272 316	high-density lipoprotein cholesterol (HDL-C)
T4	Participants 368 496	cholesteryl ester transfer protein (CETP) inhibitor that raises HDL-C and reduces LDL-C when administered alone or with a statin
T5	Participants 672 758	Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib (DEFINE)
T6	Participants 842 975	safety profile of anacetrapib in patients with coronary heart disease (CHD) or CHD risk equivalents (clinical trials.gov NCT00685776)
T7	Participants 986 1196	patients at National Cholesterol Education Program-Adult Treatment Panel III LDL-C treatment goal on a statin, with or without other lipid-modifying medications, are treated with anacetrapib, 100 mg, or placebo
T8	Participants 1315 1367	LDL-C and the safety and tolerability of anacetrapib
T9	Participants 1736 1831	2,757 patients were screened at 153 centers in 20 countries, and 1,623 patients were randomized
